Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc. (APGE), sold 20,000 shares at $82.48 ($1.7M) on 2026-04-08, disclosed to the SEC on 2026-04-10.
Scheduled sale ($1.7M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $82.48 | 17,800 | $1.5M | 88.9% |
| 2 | $83.26 | 2,000 | $167K | 10.1% |
| 3 | $85.00 | 200 | $17K | 1.0% |
| Total | $82.58 avg | 20,000 | $1.7M | 100% |
| Filing → |
| SYRE | SELL | 2026-06-23 | $2.0M | — | Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |